Should Children Get One or Two H1N1 Flu Shots?

The World Health Organization (WHO) and the United States government are having a fascinating debate about the number of H1N1 flu vaccinations that children under age 10 should receive. Both agree that two shots are better than one. The vaccine is scarce, however, so public health officials have to make hard choices about how to prioritize its use.

As NPR reported a few days ago, the WHO favors giving a single dose to each child because of the vaccine shortage:

“The priority is to give…one dose rather than vaccinate half the number of children with two doses,” says Dr. Marie-Paule Kieny, director of WHO’s Initiative for Vaccine Research.

The National Institute of Allergies and Infectious Diseases (NIAID), however, favors giving two doses to each child:

“One of the dangers in jumping ahead and saying you want to stretch out the supply by giving a single dose to these young kids,” [NIAID Director Dr. Anthony] Fauci says, “is that you’ll be under-protecting them.” If that happened, he says, we wouldn’t be saving a dose for each vaccinated child. We’d be wasting a dose.

Intrigued by this difference in opinions, I took a quick look at some of the newest vaccination data that the NIAID reported last week. Researchers examined the immune response of 583 children who received two doses of vaccine and found the following:

To use these data in developing vaccination strategies it is helpful (as I repeatedly tell my students) to consider the marginal benefits and costs associated with each shot:

The two columns on the left are the same as before. The two columns on the right measure the marginal benefits of each shot. For example, the marginal benefit of a second shot for children aged 6 to 35 months is that it increases by 75 percentage points the fraction having a strong immune response. For older children, that marginal benefit is only a 39 percentage point increase.

The figures suggest three things about the difference in opinions between the WHO and the NIAID.

1.  If you are willing to give one dose to a child aged 6-35 months, then you really ought to be willing to give that child a second dose. The second dose provides much more incremental benefit (a 75% increase vs. a 25% increase) than the first dose. In short, score one for Dr. Fauci and the NIAID.

2. For children age 3-9 years, a second dose provides much less incremental benefit than the first dose (39% for the second versus 55% for the first). If vaccine is in short supply, you are better off using it to vaccinate many 3-9 year olds once, than half as many twice. In short, score one for Dr. Kieny and the WHO.

3.  A possible compromise between the WHO and NIAID positions would be to vaccinate the youngest children twice and older children once.

Needless to say (I hope) this is not intended as any recommendation of what our vaccine policy should be. A full-fledged analysis of vaccination strategies would have to consider many other issues including differences in flu vulnerability (boosting the immune response of vulnerable individuals may yield higher public health benefits), any benefits of weak immune response (which would increase the marginal benefit of the first shot), the benefit of vaccinating older people, and the amount of vaccine available. Not to mention various measurement issues about how the immune response figures were collected (e.g., the effects of the first shot were measured after 21 days, while the effects of the second were measures after 8-10 days).

Instead, my point is simpler: that a little bit of marginal analysis can help shed light on a quite striking disagreement among public health experts.

About Donald Marron 294 Articles

Donald Marron is an economist in the Washington, DC area. He currently speaks, writes, and consults about economic, budget, and financial issues.

From 2002 to early 2009, he served in various senior positions in the White House and Congress including: * Member of the President’s Council of Economic Advisers (CEA) * Acting Director of the Congressional Budget Office (CBO) * Executive Director of Congress’s Joint Economic Committee (JEC)

Before his government service, Donald had a varied career as a professor, consultant, and entrepreneur. In the mid-1990s, he taught economics and finance at the University of Chicago Graduate School of Business. He then spent about a year-and-a-half managing large antitrust cases (e.g., Pepsi vs. Coke) at Charles River Associates in Washington, DC. After that, he took the plunge into the world of new ventures, serving as Chief Financial Officer of a health care software start-up in Austin, TX. After that fascinating experience, he started his career in public service.

Donald received his Ph.D. in Economics from the Massachusetts Institute of Technology and his B.A. in Mathematics a couple miles down the road at Harvard.

Visit: Donald Marron

3 Comments on Should Children Get One or Two H1N1 Flu Shots?

  1. Here’s the problem: We are not comparing apples to apples. Most of the other nations (Canada and the EU) who are donating vaccine to WHO are using adjuvated H1N1 vaccine by GSK and others, which contain controversial immunity booster elements along with the attenuated virus. The result?: studies in the EU show a much more robust immune response in kids after one shot vs. the non-adjuvated doses used in the US. Your tables above use data from studies of US non-adjuvated vaccine. It is expected that the percentages would vary for many WHO vaccinated kids.

Leave a Reply

Your email address will not be published.


*